| Quarterly Financials | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 33 | 30 | 93 | 60 | 33 | 122 | 49 | 50 | 43 | 27 | 39 | 30 | 23 | 24 | 35 | 28 | 16 | 26 | 34 | 28 | 34 | 37 | 40 |
| Expenses | 29 | 17 | 56 | 52 | 28 | 72 | 41 | 43 | 44 | 31 | 42 | 29 | 25 | 24 | 30 | 27 | 21 | 23 | 34 | 31 | 31 | 35 | 35 |
| EBITDA | 4 | 13 | 37 | 9 | 6 | 49 | 8 | 7 | -1 | -5 | -3 | 1 | -1 | -0 | 5 | 2 | -6 | 3 | 1 | -3 | 3 | 2 | 6 |
| Operating Profit % | 11 % | 43 % | 39 % | 13 % | 14 % | 39 % | 13 % | 11 % | -7 % | -22 % | -13 % | -3 % | -16 % | -14 % | 4 % | -19 % | -26 % | -12 % | -8 % | -15 % | 4 % | -2 % | 9 % |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Profit Before Tax | 3 | 13 | 36 | 9 | 5 | 49 | 8 | 6 | -2 | -5 | -4 | 0 | -2 | -1 | 4 | 1 | -7 | 3 | -0 | -3 | 2 | 1 | 5 |
| Tax | 1 | 3 | 9 | 2 | 1 | 13 | 2 | 2 | -1 | -1 | -1 | 0 | -0 | -0 | 1 | 1 | -2 | 1 | 0 | -1 | -0 | 0 | 1 |
| Net Profit | 2 | 9 | 27 | 6 | 4 | 36 | 5 | 5 | -1 | -4 | -3 | 0 | -2 | -1 | 3 | 0 | -4 | 2 | -1 | -3 | 3 | 1 | 4 |
| EPS in ₹ | 3.40 | 13.50 | 38.19 | 8.53 | 4.56 | 36.20 | 5.43 | 4.73 | -1.40 | -4.13 | -2.89 | 0.30 | -1.53 | -0.71 | 2.90 | 0.16 | -4.15 | 1.66 | -0.48 | -2.80 | 2.47 | 0.81 | 3.63 |
Nureca
Nureca
317.70
-1.54
(-0.48%)
Key Fundamentals
Market Cap
317.71 Cr
EPS
0.85
PE Ratio
77.62
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
447.50
52 Week Low
203.62
PB Ratio
1.61
Debt to Equity
0.02
Sector
Medical Equipment Actual
Company News
View All News
Nureca Limited received SEBI approval on October 16, 2025, for exemption from Regulation 24(ii) of Buy-Back Regulations, allowing the company to proceed with a share buyback while a merger scheme with its wholly owned subsidiary Nureca Technologies Private Limited is pending before the National Company Law Tribunal. The Board of Directors had approved the merger scheme on May 20, 2025, and shareholders approved it on June 16, 2025. SEBI granted the exemption considering that the internal restructuring involves no new equity issuance or change in shareholding pattern. The company's promoters have committed not to participate in the buyback, making it exclusively for public shareholders. The board will consider the buyback proposal at an appropriate time and comply with all applicable regulations.
Nureca Limited, a home healthcare and wellness company, announced its financial results for Q2 FY26 ended September 30, 2025. The company reported revenue of ₹37.7 crore in Q2 FY26, representing 21% year-over-year growth from ₹31.2 crore in Q2 FY25. For H1 FY26, revenue reached ₹71.9 crore, marking 40% growth from ₹51.5 crore in H1 FY25. Operating profits surged 239% year-over-year to ₹3.3 crore compared to ₹(2.4) crore in the same quarter last year. Profit after tax increased significantly to ₹3.6 crore from ₹(0.5) crore in Q2 FY25. The company attributed the performance to focused cost optimization and growth in quick commerce sales channels. Nureca operates as a digital-first healthcare company with over 93% revenue generated through online sales and maintains a debt-free, asset-light business model.
Nureca Limited's Board of Directors approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. The board meeting was held on October 16, 2025, commencing at 4:00 PM and concluding at 5:15 PM. The company operates in the home healthcare and wellness products business segment. During the quarter, Nureca filed a Scheme of Merger by Absorption for its wholly owned subsidiary Nureca Technologies Private Limited, effective from April 1, 2025, subject to regulatory approvals. The company also filed Form STK-2 for striking off its wholly owned subsidiary Nureca Healthcare Private Limited under Section 248 of the Companies Act, 2013, resulting in a write-off of investment of Rs 0.01 million. The results were reviewed by the Audit Committee and received limited review from statutory auditors.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,936.40 | #1 19,620.71 | 54.85 | #1 1,759.00 | 22.62 | #1 339 | 25.81 | 46.33 | |
315.05 | 1,731.58 | 75.17 | 242.40 | 24.12 | 25 | -50.60 | 39.29 | |
290.70 | 1,546.71 | 55.94 | 408.40 | 32.64 | 30 | -55.00 | 24.17 | |
598.00 | 993.98 | 62.04 | 249.37 | 40.00 | 17 | -20.59 | 51.82 | |
601.40 | 970.01 | 53.40 | 186.60 | 40.62 | 20 | 20.00 | 52.67 | |
510.00 | 605.30 | 32.04 | 67.10 | 13.15 | 18 | 18.92 | 35.80 | |
266.00 | 493.10 | #1 30.61 | 136.30 | #1 107.77 | 16 | 50.00 | 49.41 | |
317.70 | #8 317.71 | #10 77.62 | #7 122.10 | #7 19.24 | #10 1 | #1 820.00 | 77.90 | |
281.20 | 309.00 | 38.44 | 111.80 | -1.43 | 8 | 0.00 | 9.27 | |
268.00 | 281.76 | 37.85 | 89.85 | 0.60 | 7 | 752.54 | 41.37 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
19.24 %
Net Income Growth
-144.44 %
Cash Flow Change
-604.06 %
ROE
-147.31 %
ROCE
-222.86 %
EBITDA Margin (Avg.)
1,236.67 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 24 | 34 | 186 | 219 | 207 | 205 | 210 |
| Fixed Assets | 1 | 1 | 4 | 10 | 9 | 7 | 9 |
| Current Assets | 23 | 33 | 181 | 206 | 187 | 193 | 190 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 33 | 59 | 94 | 1 |
| Other Assets | 23 | 33 | 182 | 175 | 139 | 104 | 200 |
| Total Liabilities | 24 | 34 | 186 | 219 | 207 | 205 | 210 |
| Current Liabilities | 15 | 10 | 19 | 12 | 9 | 9 | 12 |
| Non Current Liabilities | 0 | 9 | 4 | 4 | 3 | 3 | 3 |
| Total Equity | 8 | 15 | 163 | 203 | 195 | 193 | 194 |
| Reserve & Surplus | 8 | 15 | 153 | 193 | 185 | 183 | 184 |
| Share Capital | 0 | 0 | 10 | 10 | 10 | 10 | 10 |
Cash Flow
| Cash Flow | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 0 | 0 | 17 | -9 | -8 | 14 | -11 |
| Investing Activities | -0 | -0 | -110 | -3 | -17 | 18 | 8 |
| Operating Activities | 0 | -8 | 35 | 1 | 10 | -3 | -19 |
| Financing Activities | -0 | 8 | 92 | -7 | -2 | -1 | -0 |
Share Holding
| % Holding | Jan 2020 | Feb 2021 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 93.33 % | 70.00 % | 70.00 % | 70.00 % | 70.00 % | 70.00 % | 70.00 % | 70.00 % | 70.00 % | 62.98 % | 62.98 % | 62.98 % | 63.24 % | 63.24 % | 63.24 % | 63.24 % | 63.77 % | 64.06 % | 64.30 % | 64.33 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.10 % | 0.00 % | 0.08 % | 0.08 % | 0.69 % | 0.36 % | 1.07 % | 0.08 % |
| DIIs | 0.00 % | 3.54 % | 5.71 % | 5.40 % | 5.42 % | 5.43 % | 5.23 % | 5.23 % | 0.58 % | 0.03 % | 0.02 % | 0.02 % | 0.02 % | 0.00 % | 0.02 % | 0.04 % | 0.04 % | 0.04 % | 0.04 % | 0.04 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 5.87 % | 4.49 % | 4.32 % | 5.50 % | 5.18 % | 8.49 % | 8.54 % | 25.85 % | 34.17 % | 34.06 % | 34.24 % | 34.32 % | 33.61 % | 33.73 % | 34.24 % | 32.97 % | 33.27 % | 32.39 % | 33.12 % |
| Others | 6.67 % | 20.59 % | 19.80 % | 20.28 % | 19.07 % | 19.40 % | 16.29 % | 16.23 % | 3.57 % | 2.82 % | 2.94 % | 2.76 % | 2.33 % | 3.16 % | 2.94 % | 2.41 % | 2.53 % | 2.27 % | 2.20 % | 2.45 % |
| No of Share Holders | 19 | 8,436 | 7,827 | 10,060 | 12,618 | 15,471 | 26,123 | 26,114 | 63,911 | 62,007 | 58,560 | 55,569 | 52,255 | 49,600 | 45,996 | 43,813 | 41,986 | 41,314 | 39,304 | 38,075 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2 | 3 | 0.00 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.15 | 1 | 0.00 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 23 Sept 2021 |  Dividend | ₹ 2.00 /share | 21 Sept 2021 | 1,549.00 | 1,634.10 |
| 25 Feb 2022 | Dividend | ₹ 3.00 /share | 24 Feb 2022 | 1,591.15 | 1,300.35 |
| 18 Jul 2024 |  Annual General Meeting | NA | 18 Jul 2024 | 277.90 | 275.50 |
| 24 Oct 2024 |  Quarterly Result Announcement | NA | 24 Oct 2024 | 299.65 | 299.35 |
| 24 Jan 2025 | Quarterly Result Announcement | NA | 24 Jan 2025 | 389.15 | 360.70 |
| 05 May 2025 | Quarterly Result Announcement | NA | 05 May 2025 | 248.00 | 228.80 |
| 16 Jun 2025 | Annual General Meeting | NA | 16 Jun 2025 | 228.80 | 279.00 |
| 15 Jul 2025 | Quarterly Result Announcement | NA | 15 Jul 2025 | 285.40 | 288.80 |
| 16 Oct 2025 | Quarterly Result Announcement | NA | 16 Oct 2025 | 229.70 | 235.45 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication
5 days ago
5 days agoIntimation Of Securities And Exchange Board Of India (SEBI) Order Under Section 11(1) Of SEBI Act 1992 Read With Regulation 28 Of SEBI (Buy-Back Of Securities) Regulations 2018 (Buy-Back Regulations)5 days ago
5 days agoNureca Limted Has Informed The Exchange Regarding Financial Results For The Quarter And Half Year Ended 30Th September2025.6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation6 days ago
6 days agoBoard Meeting Outcome for Nureca Limited Has Informed The Exchange Regarding Financial Results For The Quarter And Half Year Ended 30Th September2025.6 days ago
6 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20187 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Change in ManagementOct 11, 2025
Oct 11, 2025Board Meeting Intimation for Nureca Limited Has Informed The Exchange Regarding Intimation Of Board Meeting For The Declaration Of Quarterly Results And Other Business Matters.Oct 10, 2025
Oct 10, 2025Closure of Trading WindowSep 29, 2025
Sep 29, 2025Filing Of Scheme Under Regulation 37(6) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)Jul 24, 2025
Jul 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 16, 2025
Jul 16, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJul 15, 2025
Jul 15, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 15, 2025
Jul 15, 2025Board Meeting Outcome for Nureca Limited Has Informed The Exchange Regarding Unaudited Financial Results For The Quarter Ended 30Th June2025.Jul 15, 2025
Jul 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 15, 2025
Jul 15, 2025Board Meeting Intimation for Declaration Of Unaudited Standalone/Consolidated Financial Results For The Quarter Ended June 302025 Alongwith Other Business Matters .Jul 09, 2025
Jul 09, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 08, 2025
Jul 08, 2025Closure of Trading WindowJun 28, 2025
Jun 28, 2025Closure of Trading WindowJun 28, 2025
Jun 28, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJun 17, 2025
Jun 17, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJun 17, 2025
Jun 17, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJun 16, 2025
Jun 16, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2025
May 27, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 24, 2025
May 24, 2025Notice Of Annual General Meeting To Be Held On 16Th June2025May 23, 2025
May 23, 2025Annual ReportMay 23, 2025
May 23, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 22, 2025
May 22, 2025Announcement Under Regulation 30May 20, 2025
May 20, 2025Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI (Listing Obligations
And Disclosure Requirements) Regulations 2015May 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 07, 2025
May 07, 2025Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sMay 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Resignation of DirectorMay 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sMay 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-CessationMay 06, 2025
May 06, 2025Book ClosureMay 05, 2025
May 05, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 05, 2025
May 05, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 05, 2025
May 05, 2025Board Meeting Outcome for OUTCOME OF BOARD MEETING HELD ON 05 MAY 2025May 05, 2025
May 05, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 30, 2025
Apr 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 29, 2025
Apr 29, 2025Business UpdateApr 29, 2025
Apr 29, 2025Board Meeting Intimation for Consider And Approve Inter-Alia The Audited Financial Results
(Standalone And Consolidated) Along With Other Business Matters For The Fourth Quarter And Full Year Ended On March 31 2025.Apr 28, 2025
Apr 28, 2025Nureca Limited Has Informed The Exchange Regarding Business Update .Apr 21, 2025
Apr 21, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 15, 2025
Apr 15, 2025Business UpdateApr 15, 2025
Apr 15, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 12, 2025
Apr 12, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportApr 01, 2025
Apr 01, 2025Disclosure Under Regulation 7(2) Of Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations 2015.Mar 31, 2025
Mar 31, 2025Technical Indicators
RSI(14)
Neutral 76.75
ATR(14)
Volatile 15.94
STOCH(9,6)
Neutral 74.70
STOCH RSI(14)
Overbought 94.08
MACD(12,26)
Bullish 10.58
ADX(14)
Strong Trend 28.32
UO(9)
Bearish 68.74
ROC(12)
Uptrend And Accelerating 33.98
WillR(14)
Neutral -20.45
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
